Clearpoint Stock Based Compensation vs Capital Expenditures Analysis

CLPT Stock

USD 15.33 1.07 6.52%

Clearpoint Neuro financial indicator trend analysis is way more than just evaluating Clearpoint Neuro prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Clearpoint Neuro is a good investment. Please check the relationship between Clearpoint Neuro Stock Based Compensation and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.

Stock Based Compensation vs Capital Expenditures

Stock Based Compensation vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Clearpoint Neuro Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Clearpoint Neuro's Stock Based Compensation and Capital Expenditures is 0.9. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Clearpoint Neuro, assuming nothing else is changed. The correlation between historical values of Clearpoint Neuro's Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Clearpoint Neuro are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., Clearpoint Neuro's Stock Based Compensation and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Capital Expenditures

Capital Expenditures are funds used by Clearpoint Neuro to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Clearpoint Neuro operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Clearpoint Neuro's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Clearpoint Neuro current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.At this time, Clearpoint Neuro's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 165.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.5 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	973K	81K	386K	366.7K
Depreciation And Amortization	692K	777K	1.5M	1.5M

Interest Expense Depreciation And Amortization

Clearpoint Neuro fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings
Common Stock Shares Outstanding		0.81	0.46	0.21	-0.35	0.84	0.82	0.33	-0.67	-0.73	0.72	0.84	-0.14	0.74	0.93	-0.35	0.44	0.93	0.93	0.89	0.18	0.81	0.8	-0.66	-0.35	0.5
Total Assets	0.81		0.56	0.32	-0.22	0.92	0.63	0.07	-0.87	-0.59	0.96	0.65	-0.07	0.98	0.69	-0.15	0.51	0.77	0.85	0.89	0.28	0.58	1.0	-0.43	-0.14	0.42
Short Long Term Debt Total	0.46	0.56		0.28	-0.04	0.32	0.64	0.1	-0.2	-0.31	0.53	0.62	-0.14	0.53	0.47	-0.02	0.94	0.39	0.44	0.4	0.73	0.57	0.53	-0.18	-0.01	0.18
Other Current Liab	0.21	0.32	0.28		0.76	0.09	0.34	0.5	-0.13	0.24	0.22	0.29	-0.13	0.27	0.26	0.11	0.3	0.36	0.38	0.1	0.67	0.33	0.31	0.44	0.11	-0.1
Total Current Liabilities	-0.35	-0.22	-0.04	0.76		-0.46	-0.03	0.54	0.29	0.74	-0.25	-0.13	-0.34	-0.23	-0.23	0.1	0.05	-0.2	-0.18	-0.48	0.6	-0.03	-0.23	0.71	0.11	-0.62
Total Stockholder Equity	0.84	0.92	0.32	0.09	-0.46		0.57	-0.04	-0.92	-0.74	0.89	0.62	0.08	0.92	0.74	-0.12	0.24	0.8	0.86	0.92	-0.06	0.54	0.93	-0.53	-0.12	0.59
Property Plant And Equipment Net	0.82	0.63	0.64	0.34	-0.03	0.57		0.61	-0.42	-0.41	0.55	0.98	-0.38	0.55	0.91	-0.2	0.64	0.81	0.79	0.59	0.53	0.99	0.6	-0.36	-0.19	0.16
Current Deferred Revenue	0.33	0.07	0.1	0.5	0.54	-0.04	0.61		0.01	0.3	0.0	0.51	-0.68	0.0	0.43	-0.36	0.3	0.38	0.33	-0.01	0.58	0.64	0.05	0.0	-0.36	-0.46
Net Debt	-0.67	-0.87	-0.2	-0.13	0.29	-0.92	-0.42	0.01		0.51	-0.93	-0.43	-0.03	-0.92	-0.54	0.15	-0.16	-0.6	-0.68	-0.77	0.03	-0.39	-0.89	0.38	0.14	-0.41
Accounts Payable	-0.73	-0.59	-0.31	0.24	0.74	-0.74	-0.41	0.3	0.51		-0.54	-0.5	-0.29	-0.55	-0.67	0.07	-0.13	-0.61	-0.61	-0.82	0.3	-0.4	-0.59	0.68	0.07	-0.78
Cash	0.72	0.96	0.53	0.22	-0.25	0.89	0.55	0.0	-0.93	-0.54		0.56	-0.02	0.99	0.6	-0.12	0.49	0.62	0.72	0.81	0.25	0.5	0.97	-0.39	-0.12	0.41
Non Current Assets Total	0.84	0.65	0.62	0.29	-0.13	0.62	0.98	0.51	-0.43	-0.5	0.56		-0.29	0.57	0.94	-0.11	0.59	0.86	0.83	0.65	0.43	0.98	0.62	-0.37	-0.1	0.25
Non Currrent Assets Other	-0.14	-0.07	-0.14	-0.13	-0.34	0.08	-0.38	-0.68	-0.03	-0.29	-0.02	-0.29		-0.04	-0.1	0.4	-0.35	-0.11	-0.17	0.09	-0.48	-0.36	-0.05	0.21	0.4	0.76
Cash And Short Term Investments	0.74	0.98	0.53	0.27	-0.23	0.92	0.55	0.0	-0.92	-0.55	0.99	0.57	-0.04		0.61	-0.13	0.48	0.69	0.79	0.83	0.25	0.5	0.99	-0.39	-0.12	0.41
Net Receivables	0.93	0.69	0.47	0.26	-0.23	0.74	0.91	0.43	-0.54	-0.67	0.6	0.94	-0.1	0.61		-0.18	0.41	0.92	0.88	0.78	0.23	0.92	0.67	-0.47	-0.17	0.46
Common Stock Total Equity	-0.35	-0.15	-0.02	0.11	0.1	-0.12	-0.2	-0.36	0.15	0.07	-0.12	-0.11	0.4	-0.13	-0.18		-0.2	-0.19	-0.22	-0.23	-0.1	-0.18	-0.15	0.63	1.0	0.07
Non Current Liabilities Total	0.44	0.51	0.94	0.3	0.05	0.24	0.64	0.3	-0.16	-0.13	0.49	0.59	-0.35	0.48	0.41	-0.2		0.36	0.4	0.32	0.82	0.57	0.49	-0.23	-0.19	-0.03
Inventory	0.93	0.77	0.39	0.36	-0.2	0.8	0.81	0.38	-0.6	-0.61	0.62	0.86	-0.11	0.69	0.92	-0.19	0.36		0.98	0.83	0.21	0.81	0.76	-0.45	-0.19	0.45
Other Current Assets	0.93	0.85	0.44	0.38	-0.18	0.86	0.79	0.33	-0.68	-0.61	0.72	0.83	-0.17	0.79	0.88	-0.22	0.4	0.98		0.85	0.25	0.77	0.84	-0.47	-0.22	0.4
Other Stockholder Equity	0.89	0.89	0.4	0.1	-0.48	0.92	0.59	-0.01	-0.77	-0.82	0.81	0.65	0.09	0.83	0.78	-0.23	0.32	0.83	0.85		-0.01	0.57	0.88	-0.66	-0.22	0.66
Total Liab	0.18	0.28	0.73	0.67	0.6	-0.06	0.53	0.58	0.03	0.3	0.25	0.43	-0.48	0.25	0.23	-0.1	0.82	0.21	0.25	-0.01		0.48	0.26	0.22	-0.1	-0.37
Property Plant And Equipment Gross	0.81	0.58	0.57	0.33	-0.03	0.54	0.99	0.64	-0.39	-0.4	0.5	0.98	-0.36	0.5	0.92	-0.18	0.57	0.81	0.77	0.57	0.48		0.55	-0.34	-0.17	0.17
Total Current Assets	0.8	1.0	0.53	0.31	-0.23	0.93	0.6	0.05	-0.89	-0.59	0.97	0.62	-0.05	0.99	0.67	-0.15	0.49	0.76	0.84	0.88	0.26	0.55		-0.43	-0.14	0.43
Short Term Debt	-0.66	-0.43	-0.18	0.44	0.71	-0.53	-0.36	0.0	0.38	0.68	-0.39	-0.37	0.21	-0.39	-0.47	0.63	-0.23	-0.45	-0.47	-0.66	0.22	-0.34	-0.43		0.63	-0.35
Common Stock	-0.35	-0.14	-0.01	0.11	0.11	-0.12	-0.19	-0.36	0.14	0.07	-0.12	-0.1	0.4	-0.12	-0.17	1.0	-0.19	-0.19	-0.22	-0.22	-0.1	-0.17	-0.14	0.63		0.08
Retained Earnings	0.5	0.42	0.18	-0.1	-0.62	0.59	0.16	-0.46	-0.41	-0.78	0.41	0.25	0.76	0.41	0.46	0.07	-0.03	0.45	0.4	0.66	-0.37	0.17	0.43	-0.35	0.08

Click cells to compare fundamentals

Clearpoint Neuro Account Relationship Matchups

Clearpoint Neuro fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	13.2M	15.8M	20.7M	24.2M	24.6M	25.8M
Total Assets	11.9M	29.6M	65.6M	55.5M	42.7M	23.2M
Short Long Term Debt Total	2.5M	24.2M	12.3M	12.0M	13.9M	9.9M
Other Current Liab	1.7M	1.9M	2.6M	4.3M	3.6M	2.5M
Total Current Liabilities	4.0M	3.2M	4.8M	6.8M	7.4M	4.7M
Total Stockholder Equity	4.6M	2.4M	48.8M	36.9M	21.2M	22.2M
Property Plant And Equipment Net	821.4K	3.2M	2.8M	2.7M	5.0M	5.2M
Current Deferred Revenue	1.2M	562K	678K	1.1M	2.6M	2.7M
Net Debt	(3.2M)	4.1M	(41.8M)	(15.6M)	(9.2M)	(8.7M)
Accounts Payable	965.8K	300K	427K	272K	393K	373.4K
Cash	5.7M	20.1M	54.1M	27.6M	23.1M	14.1M
Non Current Assets Total	1.5M	4.2M	3.7M	4.3M	6.5M	6.8M
Non Currrent Assets Other	722.0K	648K	644K	581K	495.0K	582.8K
Cash And Short Term Investments	5.7M	20.1M	54.1M	37.5M	23.1M	14.9M
Net Receivables	1.1M	1.9M	2.3M	2.7M	3.9M	4.1M
Common Stock Total Equity	152.4K	170K	237K	246K	221.4K	263.6K
Liabilities And Stockholders Equity	11.9M	29.6M	65.6M	55.5M	42.7M	23.2M
Non Current Liabilities Total	3.3M	24.0M	12.0M	11.8M	14.1M	9.6M
Inventory	3.2M	3.2M	4.9M	9.3M	7.9M	8.3M
Other Current Assets	357.2K	488K	1.0M	1.7M	1.2M	1.2M
Other Stockholder Equity	117.2M	121.7M	182.5M	187.0M	193.4M	121.2M
Total Liab	7.3M	27.3M	16.8M	18.6M	21.5M	16.1M
Property Plant And Equipment Gross	821.4K	3.1M	2.8M	2.7M	5.9M	6.2M
Total Current Assets	10.4M	25.5M	61.9M	51.2M	36.2M	20.4M
Common Stock	152.4K	170K	237K	246K	247K	258.6K
Retained Earnings	(112.7M)	(119.5M)	(133.9M)	(150.4M)	(172.5M)	(181.1M)
Other Assets	722K	3.7M	644K	581K	668.2K	1.3M
Long Term Debt	2.1M	21.3M	9.8M	9.9M	9.9M	8.3M
Long Term Debt Total	2.1M	21.3M	9.8M	9.9M	11.4M	7.9M
Capital Surpluse	117.2M	121.7M	182.5M	187.0M	215.1M	137.6M
Property Plant Equipment	821K	3.1M	2.8M	1.3M	1.4M	1.3M
Other Liab	1.2M	215K	264K	390K	351K	505.7K
Net Tangible Assets	4.6M	2.0M	48.5M	35.9M	41.2M	43.3M
Net Invested Capital	6.7M	23.7M	58.6M	46.8M	31.1M	28.7M
Net Working Capital	6.6M	22.3M	57.1M	44.4M	28.7M	27.0M
Capital Stock	152.4K	170K	237K	246K	247K	213.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC